Biocon Biologics wins the 'ABEA : Bioprocessing Excellence in South Asia' award

Biocon Biologics wins the 'ABEA : Bioprocessing Excellence in South Asia' award

Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey

FPJ Web DeskUpdated: Tuesday, March 28, 2023, 12:22 PM IST
article-image
Biocon Biologics wins the 'ABEA : Bioprocessing Excellence in South Asia' award | Image: Biocon (Representative)

Biocon Biologics Ltd (BBL), a subsidiary of Biocon Ltd, today announced that it has won the prestigious ‘Bioprocessing Excellence in South Asia’ Award at the Asia-Pacific Bioprocessing Excellence Awards (ABEA) 2023 held in Singapore earlier this month, via an exchange filing.

Biocon Biologics is a frontrunner in the global biosimilars industry and is committed to scientific innovation, the highest standards of quality compliance and global scale manufacturing capabilities to serve patients and healthcare systems across the globe.

Commenting on the development, Kiran Kumar Gandhirajan, Site Head, Biocon Malaysia, said, “We are delighted and proud to receive the ‘Bioprocessing Excellence in South Asia’ Award. It is a recognition of our longstanding expertise in process sciences, state-of-the-art manufacturing capabilities, operational excellence and high standards of quality compliance. These strengths have enabled us to expand patient access to high quality affordable biosimilars and make a meaningful difference to global healthcare.”

Biocon Biologics was recognized as the winner as it garnered the maximum number of votes from among 70,000 biopharma professionals who participated in the survey.

The annual Asia-Pacific Bioprocessing Excellence Awards organized by IMAPAC, recognize organizations who demonstrate exceptional bioprocessing expertise and the use of best-in-class technologies and practices to achieve biomanufacturing excellence in terms of speed, reduced cost, and superior quality.

Biocon Biologics has developed multiple technology platforms that use various expression systems such as bacteria, yeast, and mammalian cells.

The Pichia Pastoris platform technology used to express recombinant proteins is a proprietary technology developed by Biocon and used for its recombinant human insulin and insulin analog products.

Similarly, the company’s scalable mammalian CHO and NSO cell-based expression platforms and robust process science expertise allow it to develop and manufacture both novel and biosimilar monoclonal antibodies for global markets.

RECENT STORIES

Lamborghini Unveils First Logo Redesign In 20 Years

Lamborghini Unveils First Logo Redesign In 20 Years

King Of Crypto In Jail: Sam Bankman-Fried Imprisoned For 25 Years

King Of Crypto In Jail: Sam Bankman-Fried Imprisoned For 25 Years

Skoda Superb Poised For Return To India – Speculated Launch On April 3!

Skoda Superb Poised For Return To India – Speculated Launch On April 3!

MGNREGA Wage Surge: Centre Announces 3-10% Wage Increase For Rural Workers; Haryana Tops At...

MGNREGA Wage Surge: Centre Announces 3-10% Wage Increase For Rural Workers; Haryana Tops At...

Banks To Stay Open On Sunday: Upon Government Request, RBI Asks Lenders To Function On March 31

Banks To Stay Open On Sunday: Upon Government Request, RBI Asks Lenders  To Function On March 31